LGD-3303
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H14ClF3N2O |
| Molar mass | 342.743 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
LGD-3303 is a drug which acts as a selective androgen receptor modulator, with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects.[1] It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.[2]
References
- ^ Vajda, Eric G.; López, Francisco J.; Rix, Peter; Hill, Robert; Chen, Yanling; Lee, Kyoung-Jin; O'Brien, Z.; Chang, William Y.; Meglasson, Martin D.; Lee, Yong-Hee (1 February 2009). "Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator". Journal of Pharmacology and Experimental Therapeutics. 328 (2): 663–670. doi:10.1124/jpet.108.146811. ISSN 1521-0103. PMID 19017848.
- ^ Vajda, Eric G; Hogue, Aimee; Griffiths, Kimberly N; Chang, William Y; Burnett, Kelven; Chen, Yanling; Marschke, Keith; Mais, Dale E; Pedram, Bijan; Shen, Yixing; van Oeveren, Arjan; Zhi, Lin; López, Francisco J; Meglasson, Martin D (1 February 2009). "Combination Treatment With a Selective Androgen Receptor Modulator q(SARM) and a Bisphosphonate Has Additive Effects in Osteopenic Female Rats". Journal of Bone and Mineral Research. 24 (2): 231–240. doi:10.1359/jbmr.081007. ISSN 1523-4681. PMID 18847323.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |